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Background: ATF5 suppresses differentiation of neuroprogenitor cells and is overexpressed 
in glioblastoma (GBM). A reduction of its expression leads to apoptotic GBM cell death. Data 
on ATF5 expression in astrocytoma WHO grade II (low-grade astrocytoma [LGA]) are scarce 
and lacking on recurrent GBM.
Patients and methods: ATF5 mRNA was extracted from frozen samples of patients’ GBM 
(n=79), LGA (n=40), and normal brain (NB, n=10), quantified by duplex qPCR and correlated 
with retrospectively collected clinical data. ATF5 protein expression was evaluated by measur-
ing staining intensity on immunohistochemistry.
Results: ATF5 mRNA was overexpressed in LGA (sevenfold, P,0.001) and GBM (tenfold, 
P,0.001) compared to NB, which was confirmed on protein level. Although ATF5 mRNA 
expression in GBM showed a considerable fluctuation range, groups of varying biological 
behavior, that is, local/multifocal growth or primary tumor/relapse and the tumor localization 
at diagnosis, were not significantly different. ATF5 mRNA correlated with the patients’ age 
(r=0.339, P=0.028) and inversely with Ki67-staining (r=-0.421, P=0.007). GBM patients 
were allocated to a low and a high ATF5 expression group by the median ATF5 overexpres-
sion compared to NB. Kaplan–Meier analysis and Cox regression indicated that ATF5 mRNA 
expression significantly correlated with short-term survival (t,12 months, median survival 
18 vs 13 months, P=0.022, HR 2.827) and progression-free survival (PFS) (12 vs 6 months, 
P=0.024). This advantage vanished after 24 months (P=0.084).
Conclusion: ATF5 mRNA expression could be identified as an additional, though not inde-
pendent factor correlating with overall survival and PFS. Since its inhibition might lead to the 
selective death of glioma cells, it might serve as a potential ubiquitous therapeutic target in 
astrocytic tumors.
Keywords: glioblastoma multiforme, recurrence, growth pattern, protein and mRNA expression
Introduction
The WHO classifies diffuse astrocytic and oligodendroglial tumors into the following 
subgroups that can be further divided by their molecular profile: diffuse astrocytoma, 
anaplastic astrocytoma, glioblastoma (GBM), diffuse midline glioma, oligodendro-
glioma, and anaplastic oligodendroglioma.1,2 Among these, isocitrate dehydrogenase 
(IDH) mutant diffuse astrocytoma WHO grade II (low-grade astrocytoma, LGA) are 
well-differentiated tumors with a comparatively good prognosis.3 However, as the char-
acteristic mutation of IDH1/IDH2 leads to genome-wide changes in DNA methylation, 
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it might represent the initial event in the development of these 
tumors.4,5 In contrast, GBM with wild-type IDH is represent-
ing the most common and aggressive form.3 Approximately 
50% of gliomas in adulthood are classified as GBM.6 Their 
recurrence tends to be the rule, with the relapse even increas-
ing in aggressiveness and resistance to therapy.7 Although 
recently Osswald et al shed light on molecular mechanisms of 
local tumor recurrence,8 not much is known about the mecha-
nisms leading to multifocal growth of astrocytic tumors. As 
astrocytic tumor cells spread wide in the brain of patients with 
unifocal tumor growth,9 the question of which mechanisms 
prevent or trigger growth of these single tumor cells arises.
Recently, tumor treating fields have been shown to be 
a promising new approach to improve GBM therapy.10–12 
Nevertheless, the prognosis of GBM patients remains rather 
unfavorable. With the current standard treatment, consisting 
of tumor resection, irradiation, concomitant temozolomide 
(TMZ) chemotherapy, and adjuvant TMZ-treatment, the 
median patient survival is only 14.6 months.13 Multifocal 
growth is even more limiting the therapeutical options and 
thereby the patients’ prognosis.14 Therefore, the identification 
of new therapeutic targets is highly relevant.
ATF5 is a widely expressed basic leucine zipper protein 
that has been classified as a member of the activating tran-
scription factor/cAMP response element binding protein 
family.15,16 At the current state of knowledge, the major 
physiological role of ATF5 is to suppress the differentiation 
of neuronal progenitor cells into glia or neurons in the normal 
brain (NB).17–19 As it has been reported to be overexpressed 
in several different tumor entities including GBM,16,20 
ATF5 could be a potential therapeutic target for a variety of 
treatment-resistant cancers with highly selective effects.21,22 
In GBM cell lines, a reduction of ATF5 activity by applica-
tion of a dominant negative peptide leads to p53-independent 
apoptotic cell death in cell culture and in mouse models. 
However, such interference did not cause any visible effects 
on NB or cultured astrocytes.21,23,24 Although data concerning 
ATF5 expression in GBM are available,23,25 data on ATF5 
expression in LGA are scarce.26 ATF5 has been shown to be 
significantly upregulated especially in invasive ductal and 
invasive lobular breast carcinomas,27 and its overexpres-
sion enhances the migratory and invasive behavior of A549 
lung carcinoma cells.28 GBM cells are highly migratory and 
invasive. However, to our knowledge, whether ATF5 might 
influence the development, time, duration, or localization 
of local or multifocal relapses of GBM has not been shown. 
Therefore, we aimed to examine the ATF5 expression in 
patients’ samples of LGA, GBM, and NB on mRNA and 
protein level and retrospectively collected clinical data to 
investigate putative effects of ATF5 expression on tumor 
growth patterns and the clinical course of the patients.
Materials and methods
Tissue samples and clinical data
Tumor samples were procured from patients treated in the 
Department of Neurosurgery of the University Hospital 
Würzburg, Germany. Written informed consent was obtained 
from the patients for the acquisition of tissue specimens as 
approved by the Institutional Review Board of the University 
of Würzburg. NB tissue specimens (n=10) for reference were 
acquired from patients diagnosed with epilepsy (n=4) and from 
autopsies of neurologically healthy patients (n=6). In addition, 
we collected IDH mutant diffuse astrocytomas WHO grade II 
(LGA, n=40) and GBM (n=79) with different growth patterns 
at first diagnosis and at relapse. We collected clinical data from 
51 patients treated between January 2011 and December 2013 
retrospectively (Table 1). The brain tumors were classified 
by routine histology based on WHO criteria.2 Immediately 
after removal, half of the respective tissue sample was frozen 
at -80°C for RNA and DNA analysis and the other half was 
formalin fixed and paraffin embedded for immunohistochem-
istry (IHC). Tissue specimens showing an estimated tumor 
cell content of ,80% were excluded. Kaplan–Meier analysis 
was performed on 42 patients, whose clinical course was fully 
reconstructable. Six patients diagnosed with multifocal primary 
tumors that did not match the diagnostic criteria for tumor 
progress were excluded from the analysis of progression-free 
survival (PFS). The extent of surgical resection was determined 
by comparing MRI images obtained before surgery with those 
obtained within 72 hours after surgery by an experienced neu-
roradiologist. Complete resection was defined as the absence 
of residual contrast enhancement on postsurgical MRI. Incom-
plete resection was specified as residual contrast enhancement 
of the size of at least one voxel on the T1-weighted image after 
microsurgical tumor excision.
The tumor volumes at primary diagnosis were mea-
sured using T1-weighted MPRage postcontrast MRIs 
(MAGNETOM Trio; Siemens, Erlangen, Germany) with 
DISPImage.29 Regions of interest (ROIs) were created 
manually on every Digital Imaging and Communications in 
Medicine (DICOM) image slide to calculate the volume of 
interest based on ROIs and slice thickness.
rna and Dna extraction
Total mRNA and genomic DNA from frozen tissue samples 
were extracted using the TRIzol® Reagent (Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufac-
turer’s instruction. DNA was stored at -80°C for further 
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usage, whereas RNA was subsequently reverse transcribed 
by using the High Capacity RNA-to-cDNA Kit (Thermo 
Fisher Scientific). cDNA concentrations were adjusted with 
distilled water to 5 ng/µL and then stored at -80°C.
Quantitative rT-Pcr
About 4 µL cDNA of each sample was analyzed with the 
StepOnePlus Real-time PCR System by using TaqMan 
Universal PCR Master Mix, GAPDH_VIC_PL (Hs99999905_
m1) as internal control and ATF5_FAM (Hs01119208_m1) 
(all from Thermo Fisher Scientific) to evaluate the relative 
ATF5 expression in a duplex setting. PCR was performed 
for 2 minutes at 50°C, followed by 10 minutes at 95°C and 
50 cycles of 15 seconds at 95°C and 1 minute at 60°C. All 
samples were run in triplicate. In case a standard deviation 
of 0.5 Ct was exceeded, the PCR was repeated.
Since biopsy- and autopsy-obtained NB tissues displayed 
a similar mRNA expression, the specimens were analyzed 
as a combined group.
ihc
IHC was performed to evaluate the IDH1 R132H mutation 
status, as well as the Ki67 and the ATF5 protein expression 
of tumor samples. Tumor sections (3 µm) were cut from 
formalin fixed, paraffin-embedded tissue blocks. Slices were 
dewaxed twice with xylene and then rehydrated in a graded 
series of ethanol (100%, 96%, 70%; diluted in distilled 
water) and in distilled water. Heat-induced epitope retrieval 
was performed at 120°C in citrate buffer (pH =6.0) for 
10 minutes. The slides were treated with 0.7% hydrogen 
peroxide to eliminate human peroxidase activity, blocked 
with 10% normal goat serum (Thermo Fisher Scientific) and 
stained using the mouse anti-IDH1 R132H antibody anti-
IDH1 R132H/DIA-H09 (Optistain; Thermo Fisher Scientific) 
diluted 1:20 in Antibody Diluent (Zytomed Systems, Berlin, 
Germany), the Ki67 Antibody M7240 (1:800; Dako Denmark 
A/S, Glostrup, Denmark) and the mouse anti-ATF5 antibody 
101-0380 (1:200; Zytomed Systems) using the Envision 
System HRP DAB (Dako Denmark A/S). The cell nucleus 
was counterstained using hemalum solution acid according to 
Mayer (Carl Roth GmbH + Co. KG, Karlsruhe, Germany).
The immunoreaction for IDH1 R132H was scored posi-
tive when tumor cells showed a strong cytoplasmic staining. 
The Ki67 staining was evaluated based on the percentage of 
cells with a specific positive staining.
For a semiquantitative evaluation of ATF5 protein 
expression, five representative areas of each sample’s ATF5 
immunostaining were photographed using a LEICA DMI 
Table 1 summary of gBM patients’ clinical data
Patient characteristics
sex Female: 19/37.3% Male: 32/62.7%
Median age at diagnosis 59 years (range 22 years–78 years)
ecOg at diagnosis 0: 26/50.9% 1: 19/37.3% .1: 6/11.8%
Tumor characteristics
Median tumor volume 24.3 ccm (range 0.22–98.8 ccm)
Tumor localization at diagnosis left hemisphere: 28/54.9% right hemisphere: 18/35.3% Both hemispheres: 5/9.8%
Tumor localization at diagnosis 
(lobe)
Frontal:
15/29.4%
Occipital:
6/11.8%
Temporal:
8/15.7%
Parietal:
5/9.8%
Multifocal:
16/31.4%
Others:
1/2%
relapse/tumor progress Primarily multifocal: 9/17.6% local relapse: 27/52.9% Multifocal relapse: 15/29.4%
iDh1 mutation WT iDh1: 36/87.8% iDh1 r132h: 5/12.2%
MgMT promoter methylation Unmethylated: 10/23.8% Methylated: 32/76.2%
Ki67 staining (median) 25% (range 10%–50%)
Therapy
Time from diagnosis to surgery 0–7 days: 28/54.9% 8–14 days: 15/29.4% .14 days: 8/15.7%
surgical intervention Biopsy: 9/17.6% complete resection: 11/21.6% incomplete resection: 30/58.5%
radiation therapy Yes: 45/93.8% no: 3/6.3%
adjuvant chemotherapy with TMZ Yes: 38/80.9% no: 9/19.1%
Outcome results
Os 0–6 months: 5/9.8% .6 months: 46/90.2%
PFs 0–6 months: 8/19% .6 months: 34/81%
Note: given are the absolute numbers of the gBM patients in each group and the percentage of the analyzed population.
Abbreviations: ecOg, eastern cooperative Oncology group scale; gBM, glioblastoma; iDh, isocitrate dehydrogenase; MgMT, O-6-methylguanine-Dna methyltransferase; 
Os, overall survival; PFs, progression-free survival; TMZ, temozolomide; WT, wildtype.
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3000 B microscope, LEICA DFC450 camera and LAS 
V4.5 software (all Leica Microsystems, Wetzlar, Germany) 
with standardized settings (magnification: 40×; exposure: 
25 ms; gain: 1.0×; gamma: 1; otherwise standard settings) 
and analyzed for staining intensity via the batch processing 
function of the open source program Fiji.30–32 The macro 
settings were as follows:
 imgName=getTitle();
 run(“Colour Deconvolution”, “vectors=[H DAB]”);
 selectWindow(imgName+“-(Colour_3)”);
 close();
 selectWindow(imgName+“-(Colour_1)”);
 close();
 selectWindow(“Colour Deconvolution”);
 close();
 selectWindow(imgName+“-(Colour_2)”);
 run(“Measure”);
 run(“Close All”);
Color deconvolution33 was used to segregate hemalum 
and 3,3′-diaminobenzidine (DAB) staining. Subsequently, 
the intensity of the 8-bit DAB pictures was measured, and 
the mean intensity was converted into OD by the formula 
OD = log (255/mean intensity).
To minimize the inaccuracy caused by visible areas with-
out tissue or strong background staining, the median OD of 
each of the five areas was taken for further analysis.
Since DAB does not follow the Beer–Lambert law and 
therefore there is no linear correlation of the antibody binding 
and DAB-intensity,34 the specimens were divided into a “high 
optical density” and a “low optical density” group by the 
median intensity to minimize the tolerated statistical error.
Methylation-specific high-resolution 
melting (hrM) analysis
DNA extracted from frozen tumor samples and human con-
trols from the Cell-to-CpG™ Methylated and Unmethylated 
gDNA Control Kit (Thermo Fisher Scientific) was treated 
with bisulfite, using the Bisulfite Conversion Kit (Thermo 
Fisher Scientific), to deaminate unmethylated cytosines into 
uracil. Then the samples were examined by HRM,35 com-
bining PCR with subsequent melting analyses of the PCR 
product using the StepOnePlus™ PCR System (Thermo 
Fisher Scientific) to determine the MGMT promoter methyla-
tion status. After bisulfite conversion, the product generated 
from unmethylated DNA has a relatively lower GC content, 
compared to the product generated from methylated DNA, 
and therefore lower melting temperatures. Forward primer 
5′-GCGTTTCGGATATGTTGGGATAGT-3′ and reverse 
primer 5′-CCTACAAAACCACTCGAAACTACCA-3′ 
were designed based on Adachi et al36 and verified using 
Methyl Primer Express® software (Thermo Fisher Scientific). 
Each reaction mixture contained 10 µL Melt Doctor™ 
HRM Master Mix (Thermo Fisher Scientific), 20 ng DNA 
template, 5 pM of each primer, filled up with RNase-free 
water to a total volume of 20 µL. The DNA was amplified 
under the following conditions: enzyme activation for 
10 minutes at 95°C, followed by 45 cycles of 15 seconds 
at 95°C and 1 minute at 60°C. The PCR concluded with 
10 seconds at 95°C, 1 minute at 60°C and the HRM for 
15 seconds at 95°C and 15 seconds at 60°C.
statistical analysis
qPCR data were statistically evaluated based on the 2-∆∆Ct 
method,37 using the triplets’ median Ct with IBM SPSS Statis-
tics 23 (IBM Corporation, Armonk, NY, USA) and checked 
for accordance to statistical evaluation considering the mean 
Ct by the help of ExpressionSuite Software v1.0.3 (Thermo 
Fisher Scientific). Groups were compared by ANOVA 
(post hoc: Scheffé Procedure). Primary tumors and subse-
quent relapses were compared by paired two-sided t-tests. 
To analyze PFS and overall survival, the patient population 
was divided by the median ATF5 overexpression (sixfold) 
into a high expression and a low expression group. Kaplan–
Meier analysis (Breslow) was used to identify differences 
in the long-term survival, whereas short-time survival was 
analyzed by means of Cox regression. Uni- and multivariate 
analyses of survival data were performed by applying the 
Cox proportional hazards model.
Melting curves were analyzed using High-Resolution 
Melting Software (Thermo Fisher Scientific) and compared 
with the control samples by calculating the “line of best fit.”
The anti-ATF5-stained specimens’ average optical 
density of NB (n=8), LGA (n=31), and GBM (n=21) were 
compared by two-sided unpaired t-tests. Due to the small 
sample number, subgroup analysis was not performed.
Known prognostic factors were compared regarding 
their relation to the PFS and the overall survival correlation 
analysis. To rule out any possible bias, the low-expression 
and high-expression groups were checked for unequal dis-
tribution (all non-parametric tests).
Results
Patient cohort
Tumor specimens of a total of 40 patients with a confirmed 
LGA WHO grade II and of 79 patients with a confirmed GBM 
were assessed for ATF5 mRNA expression. Clinical data 
were collected retrospectively for 51 of the GBM patients 
treated between January 2011 and December 2013. These 
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patients’ characteristics, details about therapy, and outcome 
results are summarized in Table 1. Nine of these patients 
had a primarily multifocal GBM, 27 patients a local primary 
GBM and local relapse, and 15 patients a local primary 
GBM and multifocal relapse. We were able to collect tissues 
from five patients from the local relapses and from one 
patient from a second relapse; we were even able to analyze 
tissues from one of the multifocal relapses. Some patients 
were partially or completely treated in external institutions. 
In addition, some analyses could not be performed due to a 
shortage of tumor specimen. Therefore, information about 
these patients’ chemotherapy (n=4), irradiation (n=3), 
MGMT promoter methylation status (n=9), IDH mutation 
(n=10), Ki67 staining (n=3), or extent of tumor resection 
(n=1) were missing.
expression of aTF5 in glioma specimen
In comparison with NB, quantitative RT-PCR revealed 
a sevenfold overexpression of ATF5 mRNA in LGA 
(P,0.001) and a tenfold overexpression in GBM (P,0.001) 
(Figure 1A). However, the ATF5 expressions in LGA and 
GBM were not significantly different.
Since the ATF5 expression in GBM was not only 
increased but also showed a considerable fluctuation range, 
Figure 1 expression of aTF5 in glioma specimen.
Notes: aTF5 mrna expression of frozen tumor samples was measured using duplex qPcr with gaPDh as endogenous marker. (A) comparison of aTF5 mrna 
expression in nB (n=10), lga (n=40) and gBM (n=79). The circles represent one statistical outlier, each. (B) expression analysis of aTF5 mrna in nB (n=10) and specimens 
of gBM showing different growth patterns (primary local tumors [n=27] and their local relapses [n=5], primary local tumors [n=15] and their multifocal relapses [n=1], and 
primary multifocal tumors [n=9]). ANOVA, Scheffé procedure, the median, and quartiles are shown; the error bars represent 95% confidence interval. (C) aTF5 was stained 
with a DAB-based protocol in paraffin-embedded specimens of NB, LGA, GBM, and peri-necrotic palisades of a GBM. Shown is one representative sample of n=8 nB, n=31 
lga, and n=21 GBM; magnification 400×. (D) Quantification of ATF5 protein expression based on the optical density of anti-ATF5-DAB staining in NB (n=8), lga (n=31), 
and gBM (n=21). Unpaired two-sided t-test with division in “high optical density” and “low optical density” groups as variable, the median, and quartiles are shown; the error 
bars represent 95% confidence interval.
Abbreviations: DaB, 3,3′-diaminobenzidine; gBM, glioblastoma; lga, low-grade astrocytoma; nB, normal brain.
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it was examined whether GBM with different growth patterns 
at first diagnosis and relapse showed varying ATF5 expres-
sions (Figure 1B). Yet, this subgroup analysis of GBM 
primary tumors that lead to local relapse, primary tumors 
that lead to multifocal relapse and multifocal primary tumors 
revealed a similar ATF5 expression (P=0.620). The same 
holds true for primary tumors and their local (P=0.928) or 
multifocal relapses (P=0.985) (Figure 1B) and for tumors 
of different localizations (left, right, or both hemispheres: 
P=0.524; frontal, occipital, temporal, parietal lobe, or multi-
focal growth: P=0.829). There was no significant correlation 
between ATF5 expression and Eastern Cooperative Oncol-
ogy Group (ECOG) scale, tumor volume, or sex (P.0.05), 
whereas the patients’ age at primary diagnosis and ATF5 
mRNA expression showed a non-parametric correlation 
(r=0.339, P=0.028). Interestingly, the proliferation index as 
determined by Ki67 staining and ATF5 mRNA expression 
significantly correlated inversely with each other (r=-0.421, 
P=0.007) (Table 2).
To evaluate whether the observed ATF5 mRNA overex-
pression by GBM compared to NB could also be confirmed 
on protein level, ATF5 IHC staining has been performed on 
8 NB, 31 LGA, and 21 GBM samples (Figure 1C). In NB 
tissues, solely the neurons, but not the astrocytes, were 
weakly stained predominantly in the cytoplasm. In contrast, 
tumor cells displayed strong nuclear staining, that was 
Table 2 correlation analysis of aTF5 mrna expression with clinical data of 42 gBM patients
Median ATF5 expression Correlation with
Above 
median ATF5
Below median 
ATF5
P-value ATF5 mRNA OS PFS
Patient characteristics
sex (female/male) 11/10 7/14 0.222 r=0.187
P=0.237
r=0.080
P=0.617
r=0.025
P=0.887
age at diagnosis (median) 67 years 
(range 47–78)
49 years 
(range 22–77)
0.003 r=0.339
P=0.028
r=-0.479
P=0.001
r=-0.473
P=0.004
ecOg at diagnosis (0/1/2/3/4) 8/11/1/0/4 14/5/0/1/4 0.113 r=-0.024
P=0.878
r=-0.020
P=0.900
r=-0.334
P=0.047
Tumor characteristics
Tumor volume (median) 23.1 ccm
(range 2.3–98.8)
45.8 ccm
(range 0.2–90.7)
0.267 r=-0.054
P=0.749
r=0.063
P=0.707
r=0.031
P=0.863
relapse/tumor progress (none/
local/multifocal)
4/13/4 2/10/9 0.151 r=-0.138
P=0.383
r=0.387
P=0.011
r=0.097
P=0.574
iDh1 mutation (wildtype/r132h 
mutation)
18/1 15/1 0.941 r=-0.011
P=0.949
r=0.301
P=0.066
r=-0.141
P=0.435
MgMT promoter methylation
(unmethylated/methylated)
3/16 6/11 0.508 r=0.015
P=0.934
r=0.336
P=0.064
r=0.272
P=0.170
Ki67 staining (median) 20% 
(range 10–35)
30% 
(range 15–50)
0.014 r=-0.421
P=0.007
r=0.050
P=0.758
r=0.332
P=0.055
Therapy
surgical intervention (biopsy/
incomplete resection/complete 
resection)
5/11/5 1/16/4 0.484 nD r=0.419
P=0.006
r=-0.073
P=0.671
radiation therapy (yes/no) 20/1 19/2 0.560 nD r=0.187
P=0.235
r=-0.286
P=0.091
adjuvant chemotherapy with TMZ 
(yes/no)
15/6 19/2 0.122 nD r=0.614
P,0.001
r=0.126
P=0.463
Outcome results
Os (median) 13 months 
(range 0–47)
18 months 
(range 0–48)
0.061 r=-0.277
P=0.076
nD nD
PFs (median) 6 months 
(range 3–21)
12 months 
(range 4–22)
0.027 r=-0.324
P=0.054
r=0.394
P=0.018
nD
Notes: Significances of distribution and correlation of clinical data were evaluated by non-parametric tests (Spearman). Significant correlations are shown in bold.
Abbreviations: ecOg, eastern cooperative Oncology group scale; gBM, glioblastoma; iDh, isocitrate dehydrogenase; MgMT, O-6-methylguanine-Dna methyltransferase; 
nD, not determined; Os, overall survival; PFs, progression-free survival; TMZ, temozolomide; WT, wildtype.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8679
aTF5 expression in astrocytic tumors
most pronounced in GBM cells localized in peri-necrotic 
palisades (Figure 1C). For semiquantitative estimation of 
protein levels, the OD was measured (Figure 1D). Compared 
to NB specimens (mean OD 37%), the staining intensity of 
LGA (mean OD 58%, P,0.001) and GBM (mean OD 57%, 
P=0.001) was significantly increased, demonstrating ATF5 
overexpression in glioma tissue specimens of different WHO 
grades on protein level. ATF5 protein expression in LGA and 
GBM was not significantly different (P=0.666).
Kaplan–Meier analysis of gBM patients 
with high and low aTF5 mrna 
expressions at primary surgery
For an assessment of the putative prognostic significance of the 
ATF5 expression level on the clinical course of the 42 GBM 
patients with complete clinical data, we divided our patient 
cohort into two groups (each n=21) based on the median ATF5 
mRNA expression at primary surgery. In the first year after 
diagnosis, a clear division of both survival curves was visible 
with a significant advantage for the lower expression group 
(median OS 18 vs 13 months in the high expression group, 
P=0.022). However, this 6 months gap diminished during the 
further course and finally vanished after 24 months (P=0.084) 
(Figure 2A, Tables 3 and 4). A similar result was obtained for 
the PFS. In the low expression group, the median PFS was 
12 months, while the PFS of the high expression group was 
6 months (P=0.024; Figure 2B, Table 5).
To rule out any bias caused by previously described 
prognostic factors, correlation analyses were performed 
for the 42 patients included in the Kaplan–Meier analysis. 
Not surprisingly, the patients’ age at primary diagnosis cor-
related significantly with both OS (r=-0.479, P=0.001) and 
PFS (r=-0.473, P=0.004). The ECOG correlated with PFS 
(r=-0.334, P=0.047). Furthermore, the extent of resection 
(r=0.419, P=0.006) and the application of TMZ chemo-
therapy (r=0.614, P,0.001) correlated with OS (Table 2). 
However, whereas the ECOG, extent of tumor resection, and 
treatment with TMZ chemotherapy were almost equally dis-
tributed between the high and low ATF5 expression groups, 
patients in the high expression group were significantly older 
(P=0.003) and showed a lower Ki67 proliferation index 
(P=0.014) (Table 2).
Uni- and multivariate analyses of survival data confirmed 
the ATF5 expression level in the tumors as prognostic, but 
not independent factor for short-term OS (t,12 months, 
HR 0.103, 95% CI 0.011–0.967, P=0.047) (Table 3) and 
PFS (12 months, HR 1.047, 95% CI 1.008–1.088, P=0.019; 
Table 5).
Discussion
ATF5 is overexpressed in a variety of tumor entities, such 
as breast, prostate, endometrium, rectal, colon, gastric, 
lung, pancreas and ovary cancer, thyroid tumors, B-cell 
chronic lymphocytic leukemia, as well as gliomas.23–25,27,38–40 
Figure 2 Kaplan–Meier analysis of gBM patients with high and low aTF5 mrna expressions at primary surgery.
Notes: gBM patients were grouped into “low aTF5 expression” and “high aTF5 expression” according to the median aTF5 mrna overexpression compared to nB 
(sixfold). Both the groups were compared for (A) Os and (B) PFs in a Kaplan–Meier analysis (Breslow).
Abbreviations: gBM, glioblastoma; m, months; Os, overall survival; PFs, progression-free survival.
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Table 3 Uni- and multivariate analyses of the Os (12 months) of 42 gBM patients
Variables Univariate model Multivariate model (P,0.001)
HR 95% CI P-value HR 95% CI P-value
sex (male) 1.654 0.427–6.403 0.466 3.589 0.662–19.454 0.138
age 1.054 0.993–1.118 0.084 0.948 0.851–1.056 0.329
aTF5 (low) 0.240 0.051–1.133 0.072 0.103 0.011–0.967 0.047
no TMZ treatment 12.721 3.480–46.498 ,0.001 29.929 1.915–467.737 0.015
no radiation therapy 6.958 1.437–33.688 0.016 18.869 2.113–168.521 0.009
Tumor resection
complete 1.000 reference 0.005    
incomplete 4.65e+07* 0–6.23e+141* 0.947    
Biopsy 3.72e+06* 0–4.99e+142* 0.937    
ECOG
4 1.000 reference 0.984    
3 0* 0 to infinity* 0.992    
2 0* 0 to infinity* 0.992    
1 0.572 0.064–5.122 0.617    
0 0.508 0.059–4.346 0.536    
iDh wildtype 22.022* 0–4.95e+06* 0.623    
Ki67 staining (%) 1.015 0.952–1.082 0.652    
Unmethylated MgMT promoter 6.605 0.686–63.591 0.102    
Notes: Uni- and multivariate analyses of the 12 months OS were performed by applying the Cox proportional hazards model. Significant values are shown in bold. 
*hr calculation was affected by limited sample size.
Abbreviations: ecOg, eastern cooperative Oncology group scale; gBM, glioblastoma; iDh, isocitrate dehydrogenase; MgMT, O-6-methylguanine-Dna methyltransferase; 
Os, overall survival; TMZ, temozolomide.
Table 4 Uni- and multivariate analysis of the Os (total) of 42 gBM patients
Variables Univariate model Multivariate model (P,0.001)
HR 95% CI P-value HR 95% CI P-value
sex (male) 1.056 0.519–2.150 0.880 1.318 0.594–2.927 0.497
age 1.053 1.015–1.092 0.005 1.058 1.009–1.110 0.020
aTF5 (low) 0.564 0.276–1.150 0.115 0.676 0.292–1.567 0.361
no TMZ treatment 11.010 3.696–32.797 ,0.001 6.585 1.917–22.623 0.003
no radiation therapy 1.310 0.306–5.600 0.716 1.687 0.360–7.913 0.507
Tumor resection
complete 1.000 reference 0.001    
incomplete 1.592 0.623–4.063 0.331    
Biopsy 9.195 2.655–31.846 ,0.001    
ECOG
4 1.000 reference 0.355    
3 0.306 0.026–3.576 0.345    
2 1.027 0.092–11.487 0.982    
1 0.342 0.073–1.611 0.175    
0 0.246 0.052–1.160 0.076    
iDh wildtype 3.942 0.516–30.131 0.186    
Ki67 staining (%) 1.002 0.958–1.048 0.928    
Unmethylated MgMT promoter 2.248 0.946–5.343 0.067    
Notes: Uni- and multivariate analyses of the OS was performed by applying the Cox proportional hazards model. Significant values are shown in bold.
Abbreviations: ecOg, eastern cooperative Oncology group scale; gBM, glioblastoma; iDh, isocitrate dehydrogenase; MgMT, O-6-methylguanine-Dna methyltransferase; 
Os, overall survival; TMZ, temozolomide.
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Table 5 Uni- and multivariate analyses of the PFs (12 months) of 42 gBM patients
Variables Univariate model Multivariate model (P,0.001)
HR 95% CI P-value HR 95% CI P-value
sex (male) 1.235 0.510–2.992 0.640 1.613 0.652–3.993 0.301
age 1.057 1.018–1.098 0.004 1.047 1.008–1.088 0.019
aTF5 (low) 0.285 0.113–0.719 0.008 0.366 0.141–0.953 0.039
no TMZ treatment 1.932 0.561–6.659 0.297    
no radiation therapy 0.047* 0–710.216* 0.533    
ECOG
4 1.000 reference 0.122    
3 3.737* 0.294–47.585* 0.310    
2 0.569 0.050–6.467 0.649    
1 0.652 0.138–3.088 0.590    
0 0.282 0.058–1.378 0.118    
iDh wildtype 0.447 0.100–2.004 0.293    
Ki67 staining (%) 0.944 0.889–1.004 0.066    
Unmethylated MgMT promoter 1.994 0.664–5.990 0.219    
Notes: Uni- and multivariate analyses of the 12 months PFS was performed by applying the Cox proportional hazards model. Significant values are shown in bold. *HR 
calculation was affected by limited sample size.
Abbreviations: ecOg, eastern cooperative Oncology group scale; gBM, glioblastoma; iDh, isocitrate dehydrogenase; MgMT, O-6-methylguanine-Dna methyltransferase; 
PFs, progression-free survival; TMZ, temozolomide.
However, the cohorts underlying the assessment of ATF5 
expression in GBM were too small to define clinical 
subgroups.23,25 Furthermore, reports on LGA are scarce, 
comprising only few specimens and merging different WHO 
grades and tumor entities into the same group for further 
analysis,26 which limits the scientific significance. Therefore, 
we extended these observations by examining a large panel 
of 79 GBM, 40 LGA, and 10 NB for ATF5 expression.
Compared to NB, we detected ATF5 protein overexpres-
sion in all LGA and GBM analyzed. ATF5 staining was local-
ized to the nuclei of the tumor cells, confirming data published 
by others.23,24 It was strongest in the peri-necrotic palisades of 
GBM, which represent the most aggressive parts of malignant 
gliomas.25 Dong et al microdissected such areas from histo-
logical GBM slides to isolate RNA and also found ATF5 to 
be overexpressed in a microarray screening.25 In our cohort, 
ATF5 mRNA and protein were clearly overexpressed in astro-
cytic tumors compared to NB, but there was no statistically 
significant difference between LGA and GBM. Likewise, 
the clinical subgroups of primary tumors and relapses with 
different growth patterns showed similar expression levels. 
Therefore, we concluded that ATF5 might be ubiquitously 
overexpressed in astrocytic tumors, independently of their 
WHO grading. Nevertheless, a striking fluctuation range of 
ATF5 mRNA expression was detectable in GBM. Thus, we 
decided to further examine the putative effect of ATF5 mRNA 
expression strength on the patients’ PFS and OS.
Some reports provide evidence that high ATF5 expres-
sion correlates with a poor prognosis in systemic cancer as 
well as in malignant glioma. In a retrospective analysis of 
23 patients with GBM, those with high ATF5 levels in their 
tumors had a substantially shorter survival than those with 
low or undetectable ATF5.24 Similar results were found in 
a microarray expression analysis of 28 GBM patients for 
differentially regulated genes in peri-necrotic palisades.25 
In contrast to these data, we could find a significant dif-
ference only in the short-term, but not in the long-term 
survival of patients categorized into ATF5 mRNA high 
and low expression groups. However, the above-mentioned 
studies analyzed only small cohorts of patients and in the 
latter 18% of the patients were still alive at final analysis. 
Unfortunately, the authors do not provide Kaplan–Meier 
plots in their publication.25 Our data suggest that low ATF5 
expression is only of temporary advantage for the patients, 
most probably due to a slower tumor growth. Indeed, high 
ATF5 expression was significantly correlated with a shorter 
PFS in our analysis.
ATF5 is discussed to be a prognostic marker for malignant 
gliomas,23–25,27 and our data support this assumption as well. 
However, to rule out any bias caused by an unequal distribu-
tion of confounding variables, we examined multiple factors 
that are known to influence GBM prognosis and progress. 
Whereas ATF5 expression was negatively associated with 
OS and PFS, ECOG, the extent of tumor resection, and the 
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application of adjuvant chemo- and/or radiation therapy were 
positively, while the age at primary diagnosis was negatively 
correlated with OS and PFS (Table 2).
Interestingly, ATF5 expression and the staining intensity 
of the proliferation marker Ki67 correlated inversely. High 
ATF5 expression is known to improve cell survival by sup-
pressing apoptotic mechanisms.41 As such expression is 
also found in neural progenitor cells,17,18 this may indicate 
that tumor cells with high ATF5 expression might support 
tumor growth by promoting cell survival and avoiding 
apoptosis24,42,43 rather than leading to a high proliferation. 
Nevertheless, Ki67 staining was elevated in GBM samples, 
although not evenly distributed throughout the slide, thus 
reflecting the high molecular intratumor heterogeneity of 
GBM tissues.44
High ATF5 expression correlated with an unfavorable 
prognosis of GBM patients and a higher age. Since age is 
known to influence the OS of GBM patients,45 this could 
mean that ATF5 might not be an independent prognostic 
marker. This assumption was supported by uni- and multi-
variate Cox analyses. Nevertheless, its general expression 
independently of WHO grading or growth pattern of the 
malignant gliomas and its clear co-correlation with a better 
PFS and short-term OS in case of low ATF5 expression might 
make it valuable as a therapeutic target.
The standard therapy of GBM consists of three major 
parts: tumor excision to decrease the tumor volume,46 
radiation for local and chemotherapy for systemic control 
of tumor growth.47 However, the spectrum of new innova-
tive therapeutic options is quite broad, comprising, among 
others, various immunotherapeutic approaches,48 targeted 
therapies,49,50 and alternating electric fields.12,50 The effects 
of such treatment strategies could probably be augmented 
by facilitating the susceptibility of tumor cells to apoptotic 
cell death.
Inhibition of ATF5 activity by a dominant negative ATF5 
protein lacking the N-terminal acidic activation and DNA-
binding domains, but containing an enhanced bZip-domain, 
or knockdown of its expression by specific siRNAs, caused 
marked apoptotic cell death of GBM cell cultures.23,51 In sub-
cutaneous and orthotopic mouse models, such constructs 
prevent or even eradicate experimental gliomas.23,51 ATF5 
expression causes radioresistance of lung cancer cells, and 
its inhibition might lead to an augmented sensitivity of such 
cells for irradiation.28 The effect of ABT263 (Navitoclax), 
a BH3-mimetic, inhibiting Bcl-2/Bcl-xL,52 is also synergis-
tically facilitated by ATF5 inhibition.22 Therefore, a 
synthetic cell-penetrating dominant negative ATF5 peptide 
CP-d/n-ATF5-S1 has been developed which proved activ-
ity against triple receptor negative breast cancer, prostatic 
carcinoma, pancreatic cancer, melanoma, non-small-cell lung 
carcinoma, hematological malignancies, colorectal cancer, 
and GBM in vitro and in six different animal models.21,22 
It can be administered intraperitoneally or subcutaneously, 
passes the blood–brain barrier at least in mice, has cross-
species efficacy, and is stable in human serum.21,22,53 This 
peptide significantly attenuates tumor growth in vivo by 
promoting apoptotic cell death of cancer cells but not of 
astrocytes or other cell types, thereby maintaining NB and 
tissue integrity.21–23
Conclusion
Thus, ATF5 might be a promising new therapeutic target not 
only for GBM in addition to the standard therapy, but for 
malignant gliomas in general, and first clinical trials could 
be readily available in the near future.
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